U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/533,420 Filing Date 04/29/2005 INFORMATION DISCLOSURE First Named Inventor Hongming Chen STATEMENT BY APPLICANT Art Unit 1743 (Use as many sheets as necessary) **Examiner Name** Gakh, Yelena

					- Carring Colorida
Sheet		3 of 8		Attorney Docket Number	TPI5020USPCT1
				DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Docu	
		Number-Kind Code <sup>2 (ff known)</sup> US-			Tiguics Appeal
		US-		1	
		US-			
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	· ·	Or Relevant Figures Appear	T <sup>6</sup>
		WO 01/51010	<del></del>	April 1980 Well from the second secon	000000000000000000000000000000000000000	
		WO 98/52047	11-19-1998	AURORA BIOSCIENCES		
		WO 00/59627	10-12-2000	MILLENNIUM PHARMA		1
		EP 0921396	06-09-1999	PFIZER		
		EP 0807811	11-19-1997	PFIZER		
		EP 0882500	12-09-1998	SUMITOMO		

Examiner	Date	
Signature	Considered	
	00110140104	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	itute for form 1449/PTO	1995, no persons are required to		on unless it contains a valid OMB control number
<b>5</b>			Application Number	10/533,420
IMI	FORMATION D	ISCI OSLIDE	Filing Date	04/29/2005
			First Named Inventor	Hongming Chen
SI	ATEMENT BY		Art Unit	1743
	(Use as many sheets a	is necessary)	Examiner Name	Gakh, Yelena
Sheet	4 of	8	Attorney Docket Number	TPI5020USPCT1

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	Number-Kind Code <sup>2</sup> (# known)			Figures Appear
		US-			
		US-			
		US-			
	<del> </del>	US-			
-		US-			
		US-			
		US-			
	<del> </del>	US-		The second secon	
		US-	<u> </u>		
		US-			
		US-			
		US-	,		
	1	US-			
		US-			
	T	US-			
		US-			
		US-	·		
		US-			
		US-			

Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ'
		EP 0553539	08-04-1993	SCHERING		
		EP 1174183	01-23-2002	SYMYX TECHNOLOGIES		
		EP 1174185	01-23-2002	SYMYX TECHNOLOGIES		
		EP 1186892	03-13-2002	SYMYX TECHNOLOGIES		

Examiner		Date	
Signature		Considered	
		00110100100	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control of the control of

Substitut	e for form 1449/PTO			Complete if Known		
0000000				Application Number	10/533,420	
INFO	ORMATION	DIS	CLOSURE	Filing Date	04-29-2005	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Hongming Chen	
	(Use as many she	ote se n	ocessary)	Art Unit	1743	
		013 43 77	occasa, y,	Examiner Name	Gakh, Yelena	
Sheet	5	of	8	Attorney Docket Number	TPI5020USPCT1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		BOWTELL, D., "Options available-from start to finish-for obtaining expression data by microarray", Nat Genet, 21 (1 Supp), pgs. 25-32 (1999)	
		BERGLUND et al., "Screening chemical and physical stability of drug substances", J. Phatmac. Biomed. Analysis, 1990, V. 8, No8-12, pp. 639-643	
200000000000000000000000000000000000000	600000000000000	BEVAN et al., "A High Throughput Screening Method for the Determination of Aqueous Drug Solubility", Anal. Chem., 2000, v. 72, pp. 1781-1787	
		BYRN et al., Pharmaceutical solids: a strategic approach to regulatory considerations", Pharmaceutical Research, 1995, v. 12, No. 7, pp. 945-54	
		CHANDLER et al., "High-throughput Screening Techniques for Pre-formulation: Salt Selection and Polymorph Studies", Acta Cryst., 2002, A58, (Supplement) C9	
		CHAYEN et al., "Microbatch crystallization under oil-a new technique allowing many small-volume crystallization trials", J. of Crystal Growth, 122: pgs. 176-80 (1992)	
		COX et al., "An investigation of protein crystallization parameters using successive automated grid searches (SAGS)", J. of Crystal Growth, 90: pgs. 318-324 (1988)	
		CRAW et al., "Case based design for Tablet Formulation", proc. 4th Eur. Workshop on Case based Reasoning, pgs. 358-369 (1998)	
		CREESE, "Receptor Binding as a Primary Drug Screen", Neurotransmitter Receptor Binding, 2nd Ed., Ch. 9, pgs. 189-233 (1985)	
		ECKSTEIN et al., Unattended, Robotic Drug-Release Testing of Enterically Coated Aspirin", Anal. Chem., 58: pgs. 2316-2320 (1986)	

	Examiner	Date	
-	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO				Complete if Known
Cabolita				Application Number	10/533,420
INFO	DRMATION	DIS	CLOSURE	Filing Date	04-29-2005
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Hongming Chen
	(Use as many she	ets as ni	ecessarvi	Art Unit	1743
	(OSC OS Many SNC		occosury)	Examiner Name	Gakh, Yelena
Sheet	6	of	8	Attorney Docket Number	TPI5020USPCT1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Food and Drug Administration, "International Conference on Harmonisation: Draft Guideline on Impurities" Federal Register 62: pgs. 24302-09 (1997)	
		GARDNER, "Application of High-Throughput Technologies to Drug Substance and Drug Product Development", FOCAPO, 12 January 2002	
		GEORGE et al., "Automated dissolution testing of sustained release tablets", American Laboratory 20: pgs. 106-112 (1988)	
		GOLD et al., "Effects of Selective U.S.P. Talcs on Acetylsalicylic Acid Stability in Tablets", Journ. Pharm. Sci., 53(1), pgs. 52-54 (1964)	
		GORDON et al., "Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions", J. Med. Chem., 37(10), pgs. 1384-1401 (1994)	
		HILFIKER et al., Polymorphism - integrated approach from high-throughput screening to crystallization optimization", Journal of Thermal Analysis amd Calorimetry, 2003, v. 73,	
		IYER et al., "Studies on Instantaneous release of Drug Compounds for Microfluidic High-throughput Screening Applications", Polymer Preprints: ACS, Division of Polymer Chemistr	
		KORNBLUM, ' Stability Studies of Small Solid Dosage Forms", Drug & Cosmetic Industry, 1970, v. 106, No. 4, pp. 141-146	
		LENCZEWSKI et al., "Automated Screening Method for Determining Optimum Preservative Systems", Journal of AOAC International, 81: pgs 534-9 (1998)	
		LENNERNAS, "Human Intestinal Permeability", Journal of Pharm. Sci., 87: pgs. 403-410 (1998)	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, DA Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control.

	te for form 1449/PTO				Complete if Known
				Application Number	10/533,420
		_	CLOSURE	Filing Date	04-29-2005
STA	STATEMENT BY APPLICANT		First Named Inventor	Hongming Chen	
	(Use as many she	ets as n	ecessary)	Art Unit	1743
		010 00 17		Examiner Name	Gakh, Yelena
Sheet	7	of	8	Attorney Docket Number	TPI5020USPCT1

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LIPINSKI et al., "Aqueous Solubility in Discovery, Chemistry, and Assay Changes", Methods and Principles in Medicinal Chemistry, 2003, 18 (Drug Bioavailability), pp. 215-231	
		LIPINSKi et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery", Advanced Drug Delivery, 2001, v. 46, pp. 3-26	
		LITTLECHILD et al., "Protein crystallization: magical or logical: can we establish some general rules?", J. of Physics, pgs. 111-118 (1991)	
		MARTIN et al., "Automation of Microtiter Plate-Chromogenic Substrate LAL Endotoxin Assay Method", J. of Parenteral Science and Technology, 4: pgs. 61-6 (1986)	
		MCFARLAND et al., "Combinatorial approaches to materials discovery", Trends Biotechnol., 17(3): pgs. 107-115 (1999)	
		MEHTA, "Issues and approaches for improving the solubility and bioavailability of poorly water soluble compounds", Bulletin Technique Gattefosse, 1998, v. 91, pp. 65-72	
		MERE et al., "Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening", August 1999 DDT, 4(8), pgs. 363-369	
		MERRITT, A.T., "Uptake of new technology in lead optimization for drug discovery", 1998 DDT, 3(11), pgs. 505-510	
		MORELOCK et al., "Estimation and Correlation of Drug Water Solubility with Pharmacological Parameters Required for", J. Pharm. Sci., 1994, v. 83, No. 7, pp. 498-52	
		PROMEGA, Inc., "Cell Titer 96 AQueous One Solution Cell Proliferation Assay", 1996 Neural Notes, 11(3), 15	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO	uotron 7 to	k or rese, he persons ar	o required to respond to a concentration	Complete if Known
Guddina				Application Number	10/533,420
			CLOSURE	Filing Date	04-29-2005
STA	STATEMENT BY APPLICANT			First Named Inventor	Hongming Chen
	(Use as many she	ets as n	ecessarvi	Art Unit	1743
	(OSC US MUNY SHO			Examiner Name	Gakh, Yelena
Sheet	8	of	8	Attorney Docket Number	TPI5020USPCT1

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	2
Initials*	No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		SHARMA et al., "Pharmaceutical and Physical Properties of Paclitaxel (Taxol) Complexes with Cyclodextrins", J. Pharm. Sci., 84, 10, pgs. 1223-1230 (1995)	
		SONG et al., "Controlled release of U-86983 from double-layer biodegradable matrices: effect of additives", J. Cont. Rel., 45(2), pgs. 177-192 (1997)	
		TAKAI et al., "Optimum Formulation of Griseofulvin/Hydroxypropyl Cellulose Solid Dispersions with Desireable", Chem. Pharm. Bull., 32(5), pgs. 1942-7 (1984)	
		WANG et al., "A New Ultra-high Throughput Method for Characterizing", Rapid Commun. in Mass Spectrom., 12, pgs. 1123-1129 (1998)	
		WARD et al., "Automatic preparation of protein crystals using laboratory robotics and automated visual inspection", J. of Crystal Growth, 90, pgs. 325-339 (1988)	
		"1998 ARES Meeting Wine Tasting" Online! XP002248070, Retrieved from the Internet: URL:http://www.aresnet.org/ARES/meetings 1998Wine.html retrieved on 7/15/2003	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO

Sheet

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Con	nplete if Known	
Application Number	10/533,420	
Filing Date	04-29-2005	
First Named Inventor	Hongming Chen	
Art Unit	1743	
Examiner Name	Gakh, Yelena	
Attorney Docket Number	TPI5020USPCT1	

	•		U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<u> </u>		00 40 4075	0	Tigaloo Appoul
		<sup>US-</sup> 3,899,011	08-12-1975	Curtiss	
		<sup>US-</sup> 5,859,703	01-12-1999	Aldridge et al.	
		<sup>US-</sup> 5,417,923	05-23-1995	Bojanic et al.	
		<sup>US-</sup> 4,399,687	08-23-1983	Collins	
		<sup>US-</sup> 5,843,767	12-01-1998	Beattie	
		<sup>US-</sup> 5,985,214	11-16-1999	Stylli et al.	
		<sup>US-</sup> 5,490,415	02-13-1996	Mak et al.	
		US- 5,503,843	04-02-1996	Santus et al.	
		<sup>US-</sup> 6,271,038	08-07-2001	Liu et al.	
		<sup>US-</sup> 6,296,673	10-02-2001	Santarsiero et al.	
		<sup>US-</sup> 4,808,705	02-28-1989	Ferris, R.	
		<sup>US-</sup> 5,746,982	05-05-1998	Saneii et al.	
		<sup>US-</sup> 2001/0016631	08-23-2001	Freitag et al.	
		<sup>US-</sup> 2001/0055775	12-27-2001	Schultz et al.	
		us- 2002/0023507	02-28-2002	Hajduk et al.	
		US- 2002/0029621	03-14-2002	Hajduk et al.	
		<sup>US-</sup> 2002/0032531	03-14-2002	Mansky et al.	
		<sup>US-</sup> 2002/0037647	03-28-200	Hwang et al.	
		<sup>US-</sup> 2002/0048610	04-25-2002	Cima et al.	

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	;	Or Relevant Figures Appear	T <sup>6</sup>
		WO 94/11489	05-26-1994	BIOLOG, INC.		
		WO 96/06842	03-07-1996	PFIZER LIMITED		
		WO 96/16078	05-30-1996	PFIZER LIMITED		
		WO 99/08112	02-18-1999	SUPRATEK PHARMA INC.		
		WO 98/40159	09-17-1998	TREGA BIOSCIENCES, INC		
		WO 98/47613	10-29-1998	SYMYX TECHNOLOGIES		

Examiner	Date	
Signature	Considered	
l		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TPI5020USPCT1

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

Application Number 10/533,420

Filing Date 04/29/2005

First Named Inventor Hongming Chen

Art Unit 1743

Examiner Name Gakh, Yelena

Sheet

Attorney Docket Number

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US- 2003/0162226	00 00 0000	Cinn of all	
	ļ	2003/0162226	08-29-2003	Cima et al.	
		US-			
	<del> </del>	US-			
	l	US-			
		US-			
		US-			
	ļ	US-			
		US-			
	<u> </u>	US-			
	<u> </u>	US-	<del>- </del>		
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3 *</sup> Number * *Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear			
						Τ°		
		WO 98/52614	11-26-1998	BOARD OF TRUSTEES OF				
		WO 99/04247	01-28-1999	SYMYX TECHNOLOGIES				
		WO 99/06814	02-11-1999	SARNOFF CORPORATION				
		WO 00/03240	01-20-2000	CETEK CORPORATION				
		WO 00/29987	05-25-2000	UNIV OF MARYLAND				
		WO 02/31477	04-18-2002	SYMYX TECHNOLOGIES				

Examiner		Date	11/20/2008
Signature	/Yelena Gakh/	1 2	11/20/2000
Signature	Torona Santa	Considered	
		1 '	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.